Baxter International (BAX) reported $2.7 billion in revenue for the quarter ended March 2026, representing a year-over-year increase of 2.9%. EPS of $0.36 for the same period compares to $0.55 a year ago.
The reported revenue compares to the Zacks Consensus Estimate of $2.6 billion, representing a surprise of +3.74%. The company delivered an EPS surprise of +15.42%, with the consensus EPS estimate being $0.31.
While investors scrutinize revenue and earnings changes year-over-year and how they compare with Wall Street expectations to determine their next move, some key metrics always offer a more accurate picture of a company's financial health.
As these metrics influence top- and bottom-line performance, comparing them to the year-ago numbers and what analysts estimated helps investors project a stock's price performance more accurately.
Here is how Baxter performed in the just reported quarter in terms of the metrics most widely monitored and projected by Wall Street analysts: Net Sales- Pharmaceuticals- International: $441 million versus the two-analyst average estimate of $412.19 million. The reported number represents a year-over-year change of +14.3%. Geographic Net Sales- United States: $1.44 billion compared to the $1.42 billion average estimate based on two analysts. Net Sales- Other- International: $39 million compared to the $29.43 million average estimate based on two analysts. The reported number represents a change of +30% year over year. Net Sales- Infusion Therapies and Technologies- International: $455 million compared to the $434.6 million average estimate based on two analysts. The reported number represents a change of +11% year over year. Net Sales- Pharmaceuticals: $621 million compared to the $582.11 million average estimate based on four analysts. The reported number represents a change of +6.9% year over year. Net Sales- Advanced Surgery: $304 million versus the four-analyst average estimate of $291.29 million. The reported number represents a year-over-year change of +13.4%. Net Sales- Other: $90 million versus $80.06 million estimated by four analysts on average. Compared to the year-ago quarter, this number represents a +15.4% change. Net Sales- Front Line Care: $270 million compared to the $282.71 million average estimate based on four analysts. The reported number represents a change of -2.5% year over year. Net Sales- Drug Compounding: $320 million versus $274.25 million estimated by four analysts on average. Compared to the year-ago quarter, this number represents a +30.1% change. Net Sales- Care and Connectivity Solutions: $435 million compared to the $439.46 million average estimate based on four analysts. The reported number represents a change of +1.9% year over year. Net Sales- Medical Products and Therapies: $1.29 billion versus the four-analyst average estimate of $1.24 billion. The reported number represents a year-over-year change of +1.8%. Net Sales- Healthcare Systems and Technologies: $705 million versus $722.17 million estimated by four analysts on average. Compared to the year-ago quarter, this number represents a +0.1% change.View all Key Company Metrics for Baxter here>>>
Shares of Baxter have returned +0.7% over the past month versus the Zacks S&P 500 composite's +12.2% change. The stock currently has a Zacks Rank #4 (Sell), indicating that it could underperform the broader market in the near term.Radical New Technology Could Hand Investors Huge Gains
Quantum Computing is the next technological revolution, and it could be even more advanced than AI.
While some believed the technology was years away, it is already present and moving fast. Large hyperscalers, such as Microsoft, Google, Amazon, Oracle, and even Meta and Tesla, are scrambling to integrate quantum computing into their infrastructure.
Senior Stock Strategist Kevin Cook reveals 7 carefully selected stocks poised to dominate the quantum computing landscape in his report, Beyond AI: The Quantum Leap in Computing Power .
Kevin was among the early experts who recognized NVIDIA's enormous potential back in 2016. Now, he has keyed in on what could be "the next big thing" in quantum computing supremacy. Today, you have a rare chance to position your portfolio at the forefront of this opportunity.
See Top Quantum Stocks Now >>Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report
Baxter International Inc. (BAX): Free Stock Analysis Report
This article originally published on Zacks Investment Research (zacks.com).